The innovation.The impact. The value.

Social Impact

Social impact

What if a virtual copy of a person could predict a disease before it developed?

The UAE case

Over recent years, the UAE’s healthcare system has made a marked shift toward a far more preventive model. The federal health ministry has had prevention in its name since 2016, the National Strategy for Wellbeing 2031 was launched in 2019, and in June 2024 the Emirates Genome Council approved a national framework for personalized and preventive medicine. Importantly, doctors can only practice that kind of medicine with technology that tells them which patients are likely to develop a disease, and BioTwin provides exactly that.

The social impact

BioTwin’s technology reads a person’s biomarkers, biometrics, clinical records and the data from their wearable devices, and it uses that information to build a virtual twin of the person which is updated as their data changes. Because the twin can detect and predict disease early, a doctor can act before an illness has developed, which means that medicine becomes both personalized and preventive. In the UAE, BioTwin is being used first in oncology, and the company also works in cardiology, neurology and metabolic health.

What MBRIF made possible

BioTwin developed its technology in Canada and joined the Innovation Accelerator in January 2026 as one of the 21 companies in Cohort 11. For a company arriving from outside the country, the Accelerator provides a coach and mentors, and it makes introductions to the industry partners and investors the company needs – shortening the time between a first pilot and a service that patients can actually use.

Social impact in numbers

An innovation for personalized, preventive medicine

BioTwin

Once a person has a virtual twin, their doctor can run simulations on it that could never be run on the person themselves, which means that disease can be predicted as well as detected.

2026

Joined the Innovation Accelerator,Cohort 11

INNOVATION ACCELERATOR COHORT 11